Not only does MNTA is blazing the trail for biosimilar drugs using their proprietary tech in detailed structural analysis of complex compounds, they've turned this know-how towards characterizing patient populations to better design new drugs... this company is on the go!... But, on April 14 Zack says sell... and they continue on that stance?... April fools anyone?.... all imho k
they've sold 5.1 Million shares to raise $70.3 million of the $75 million target. Much of that went to FMR. They absorbed 3.5 million shares according to latest SEC filing. They filed to have another $75 million to maintain capital needed for 1 1/2 to 2 years.
End of year financial says they have $192 million cash. They expected to burn $30 million in the first quarter. They've raised a total of $51 mill with ATM since the beginning of the year. And they received another $10 million the other day because of the approval. Their financials is solid. Their science is astoundingly excellent... I think we got a winner here .... all imho k
yes, payers run the show...
another scenario 4. patients that co-pays. in a typical 20-80 split, a patient's portion is $13,000. Would that patient go to or revert back to a cheaper generic if (s)he saves $3,000? i'll go out on a limb here and say absolutely.
These dynamics will play out as Glatopa goes to market... the mantra is MONEY talks.
MNTA asserts that they've learn their lesson on the Amphastar fiasco. They've worded their patents accordingly. The FDA dropped the ball on that one and they are making sure it won't happen again. Other generics will need to make their own drugs without MNTA's IP.
all imho k
Baxter now wishes they have not terminated their ORENCIA collaboration with MNTA... MNTA stands to have this market on their own now.... k
90%?... nah! you're far off, imo... If you listened to the CC and previous presentations management is confident that they will capture a good portion of the MS market.
Right now TEVA have 63% of the existing market switched over to 3x.... here's the scenarios that will play out in the market....
1. new patients will go to Sandoz/MNTA because it will be cheaper than branded product (Copaxone)
2. Payers(insurance companies) will encourage those that are on the 3 times a week to revert back to the once a week since it will be cheaper... remember drug costs $65,000. per year per patient.... if payers can revert them back because they will save say $15,000 dollars per person per year, you can confidently bet that they will encourage patients to revert back to 7x.
3. There are competing treatment out there. But Copaxone is a very effective drug for MS... and since Glatopa is equivalent to Copaxone but cheaper it will get all the switch over from those other competing drugs... all imho... k
i've listened to the CC. It seems like the FDA will use MNTA's science as a measuring standard for other entries... and no matter how many entrants they will maintain a 50/50 split... k
This profound fact is the defining moment for MNTA... AbbVie is quaking... Humira is at the crosshairs of MNTA and Baxter... it is next to fall... 2017 here we come!.... k
MNTA bats a 1000!!!.. 2 for 2... Lovenox and Copaxone.... they take two drugs to the FDA and the get two approval... who is the biotech arena does this kind of stuff? ... as far as I know no one!... MNTA has first class scientists and management... I know... k
they blew it big time on April 14... They are still downplaying the importance of the FDA approval... MNTA is batting a thousand in the drug approval field!!!!... they took 2 drugs to the FDA and the FDA approved 2 of those drugs!... how many in the biotech field has done this?... I can't think of anyone.... Zacks Scukk!... imo... k
w o guy, of course i'm funny dude!... it helps take away the sting of a losing position...well i'm still in the green but shrinking every day.... thanks for the thumbs up brahdah!... k
e2w, I like it when you write one liners... the long superfluous posts are too much for me... 2 sentences is all I can take...
No one is perfect?... you ought to meet my friend Big Kahuna.... he thinks he is... k
wyattkap, The management is to blame. They've given the shorts the ammunition to do their thing to our stock once again. They're not forthcoming. Go back to the press release on January 12. You'll see that they've stumbled big time. They try to power through the FDA by using preclinical data!?... Is this company run by stoogies?... imho k
Management revealed that they filed IND for this study prior to Feb 9 earnings conference call. that should be enough time for them to get ready when the FDA gives the green light. So it is not just one month. It is more than 3 months!
This kind of delay is unacceptable. It is giving the shorts to pounce again. Thanks to the ineptitude of management we're back to $7 again.